BioCardia, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
BioCardia, Inc. (BCDA) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $229.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-24
- BioCardia, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $229.00K, a 41.36% increase from fiscal 2024.
- BioCardia, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $162.00K, a 39.33% decline from fiscal 2023.
- BioCardia, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $267.00K, a 8.25% decline from fiscal 2022.
- BioCardia, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $291.00K, a 4.30% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $229.00K 10-K · filed 2026-03-24 |
| 2024-12-31 | $162.00K 10-K · filed 2026-03-24 |
| 2023-12-31 | $267.00K 10-K · filed 2025-03-26 |
| 2022-12-31 | $291.00K 10-K · filed 2024-03-27 |
| 2021-12-31 | $279.00K 10-K · filed 2023-03-29 |
| 2020-12-31 | $276.00K 10-K · filed 2022-03-29 |
| 2019-12-31 | $225.00K 10-K · filed 2021-03-30 |
| 2018-12-31 | $236.00K 10-K · filed 2020-04-09 |
| 2017-12-31 | $135.00K 10-K · filed 2020-04-09 |
| 2016-12-31 | $89.00K 10-K · filed 2019-04-02 |
| 2015-12-31 | $51.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |